Chlamydia trachomatis serology in women with and without ovarian cancer.
Pelvic inflammation has been implicated in the genesis of ovarian cancer. We conducted serologic measurements of Chlamydia trachomatis antibodies as a surrogate marker of chlamydial pelvic inflammatory disease. Women with ovarian cancer (n = 521) and population-based controls (n = 766) were tested. IgG antibodies to serovar D of chlamydia elementary bodies (EBs) were detected using an ELISA assay. The odds of having ovarian cancer among women with the highest titers (>or=0.40 OD units) were 0.6 (95% CI 0.4-0.9). These data do not support our earlier finding of elevated titers for antibodies to C. trachomatis among women with ovarian cancer.
Ness
Roberta B
RB
School of Public Health, University of Texas, Houston, TX 77030, USA. roberta.b.ness@uth.tmc.edu
Shen
Caixia
C
Bass
Debra
D
Jackson
Carlynn
C
Moysich
Kristen
K
Edwards
Robert
R
Brunham
Robert C
RC
D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood*; D016022:Case-Control Studies; D002690:Chlamydia Infections / Q000097:blood / Q000150:complications / Q000276:immunology*; D002692:Chlamydia trachomatis / Q000276:immunology* / Q000302:isolation & purification; D016001:Confidence Intervals; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000097:blood*; D016015:Logistic Models; D008875:Middle Aged; D016017:Odds Ratio; D010051:Ovarian Neoplasms / Q000097:blood / Q000150:complications / Q000276:immunology* / Q000382:microbiology; D000292:Pelvic Inflammatory Disease / Q000150:complications / Q000382:microbiology; D012307:Risk Factors
D000907:Antibodies, Bacterial; D007070:Immunoglobulin A; D007074:Immunoglobulin G